Axsome Therapeutics Inc
AXSM100.924USD
-2.096-2.03%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
4.97BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Axsome Therapeutics Inc Unternehmen
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Unternehmensinformationen
BörsenkürzelAXSM
Name des UnternehmensAxsome Therapeutics Inc
IPO-datumNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Anzahl der mitarbeiter683
WertpapierartOrdinary Share
GeschäftsjahresendeNov 19
AddresseOne World Trade Center, 29Th Floor
StadtNEW YORK
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl10007
Telefon12123323241
Websitehttps://www.axsome.com/
BörsenkürzelAXSM
IPO-datumNov 19, 2015
CEODr. Herriot Tabuteau, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Nach RegionUSD
Name
Umsatz
Anteil
United States
119.41M
98.31%
Outside of the United States
2.05M
1.69%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Aktionärsstatistik
Aktualisiert: Sat, Jul 12
Aktualisiert: Sat, Jul 12
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Aktionäre
Aktionäre
Anteil
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
33.54%
Investment Advisor/Hedge Fund
22.21%
Corporation
14.92%
Hedge Fund
14.24%
Research Firm
2.73%
Private Equity
1.51%
Individual Investor
1.39%
Pension Fund
1.17%
Sovereign Wealth Fund
0.82%
Other
7.48%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
614
46.10M
93.63%
-4.69M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
2023Q1
467
40.73M
95.65%
-3.70M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Antecip Capital, L.L.C.
7.34M
14.92%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.87M
7.86%
-26.20K
-0.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
6.03%
-40.30K
-1.34%
Mar 31, 2025
RTW Investments L.P.
2.92M
5.94%
-1.13M
-27.86%
Mar 31, 2025
BVF Partners L.P.
1.69M
3.43%
+302.16K
+21.77%
Mar 31, 2025
Macquarie Investment Management
976.26K
1.98%
+12.21K
+1.27%
Mar 31, 2025
Geode Capital Management, L.L.C.
934.85K
1.9%
+22.32K
+2.45%
Mar 31, 2025
Fidelity Management & Research Company LLC
916.73K
1.86%
+275.45K
+42.95%
Mar 31, 2025
State Street Global Advisors (US)
906.02K
1.84%
-41.23K
-4.35%
Mar 31, 2025
Fairmount Funds Management LLC
815.18K
1.66%
-653.81K
-44.51%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
SPDR S&P Pharmaceuticals ETF
3.7%
ALPS Medical Breakthroughs ETF
3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.62%
Tema Neuroscience and Mental Health ETF
2.52%
iShares U.S. Pharmaceuticals ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.89%
First Trust Mid Cap Growth AlphaDEX Fund
0.6%
iShares Health Innovation Active ETF
0.59%
Invesco Nasdaq Biotechnology ETF
0.57%
ProShares Ultra Nasdaq Biotechnology
0.57%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil3.7%
ALPS Medical Breakthroughs ETF
Anteil3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil2.62%
Tema Neuroscience and Mental Health ETF
Anteil2.52%
iShares U.S. Pharmaceuticals ETF
Anteil2.17%
Virtus LifeSci Biotech Products ETF
Anteil1.89%
First Trust Mid Cap Growth AlphaDEX Fund
Anteil0.6%
iShares Health Innovation Active ETF
Anteil0.59%
Invesco Nasdaq Biotechnology ETF
Anteil0.57%
ProShares Ultra Nasdaq Biotechnology
Anteil0.57%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
